. Author manuscript; available in PMC: 2016 Apr 2.

Published in final edited form as: Breast Cancer Res Treat. 2015 Apr 2;150(3):569–579. doi: 10.1007/s10549-015-3359-6

Table IIC.

Tumors with presence or absence of ≥2+ PARP1 staining analyzed according patient and tumor characteristics (Race, ER status, PR status, HER2 status).

		Yes	No	Total	Odds Ratio	CI	P-value

Race	White	108 (52.94)	44 (42.72)	152	>999.999	<0.001->999.999	0.9315
	Black	96 (47.06)	58 (56.31)	154
	Other	0 (0)	1 (0.97)	1

ER	ER+	78 (38.24)	60 (58.25)	138	0.532	0.160-1.773	0.3640
ER	ER-	126 (61.76)	43 (41.75)	169	0.532	0.160-1.773	0.3640

PR	PR+	72 (35.29)	56 (18.24)	128	0.979	0.296-3.237	0.7193
PR	PR-	132 (64.71)	47 (45.63)	179	0.979	0.296-3.237	0.7193

HER2	HER2+	68 (33.33)	25 (24.27)	93	3.081	1.607-5.906	0.0019
HER2	HER2-	136 (66.67)	78 (75.73)	214	3.081	1.607-5.906	0.0019

Stage	0	1 (0.50)	0 (0)	1	>999.999	<0.001->999.9	0.9127
	1	55 (27.64)	22 (21.78)	77	1.095	0.128-9.392
	2	94 (47.24)	49 (48.51)	143	1.366	0.176-10.610
	3	46 (23.12)	28 (27.72)	74	0.969	0.120-7.813